Caxton Associates LLP Makes New Investment in DaVita Inc. $DVA

Key Points

• Caxton Associates LLP acquired a $513,000 stake in DaVita Inc., purchasing 3,352 shares in the first quarter.
• Goldman Sachs increased its stake in DaVita by 19.1%, owning 179,140 shares valued at approximately $27.4 million after the purchase.
• DaVita's stock has a consensus rating of "Reduce" with a target price of $158.00, following recent price adjustments from several brokerages.

Caxton Associates LLP acquired a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 3,352 shares of the company's stock, valued at approximately $513,000.

Several other large investors have also recently added to or reduced their stakes in DVA. GAMMA Investing LLC increased its position in DaVita by 14,695.8% during the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock worth $35,919,000 after buying an additional 233,222 shares during the period. Doma Perpetual Capital Management LLC increased its position in shares of DaVita by 172.3% in the first quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company's stock worth $44,110,000 after purchasing an additional 182,476 shares during the period. Northern Trust Corp increased its position in shares of DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company's stock worth $136,240,000 after purchasing an additional 149,858 shares during the period. Nuveen LLC bought a new position in shares of DaVita in the first quarter worth $20,218,000. Finally, Rovin Capital UT ADV bought a new position in shares of DaVita in the first quarter worth $18,442,000. Institutional investors own 90.12% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Truist Financial set a $148.00 price objective on DaVita in a research note on Friday, August 8th. Bank of America reduced their price objective on DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a research note on Wednesday, September 10th. Barclays reduced their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 7th. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Saturday. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average price target of $158.00.

DaVita Trading Down 1.7%

Shares of DVA traded down $2.22 during mid-day trading on Monday, reaching $130.95. 633,318 shares of the company were exchanged, compared to its average volume of 848,063. DaVita Inc. has a 52 week low of $126.07 and a 52 week high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The stock has a market capitalization of $9.36 billion, a PE ratio of 12.88, a PEG ratio of 0.95 and a beta of 1.13. The business has a 50 day simple moving average of $138.45 and a two-hundred day simple moving average of $141.47.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same period last year, the company earned $2.00 earnings per share. The firm's revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.50% of the company's stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.